Assessment the efficacy of amanadine hydrochloride in improving the function of patients with diffuse axonal damage after acute severe cerebral trauma

Abstract

The aim of this study was to evaluate the efficacy of amantadine in improving the cognitive function of patients with diffuse axonal injury after TBI. Method and materials: All patients with severe head injury (GCS < 8) admitted in Tabriz's Imam Hospital between January 1, 2017 and December 31, 2019. 57 patent are included this randomized clinical trial. The patients were divided into two groups based on the fact, whether they did or did not receive amantadine 200 mg twice Times of day included in standard therapy. The results were analyzed by SPSS (ver.21) software. Results: From the 57 patients studied, 28 patients were in the placebo group with an average age of 28.86 and initial GCS at admission of 1.69 ± 5.25. The primary score of the DRS in this group was 20.42 ± 4.7 and the initial GOS score was 2.71 ± 0.72 and the mortality rate was 10.71% . 29 patients were in the amantadine treatment group with an average age of 29.79 and initial GCS at admission of 1.54 ± 5.58. The primary score of DRS in this group was 19.93 ± 5.2, and the initial GOS score was 2.86 ± 0.73 and the mortality rate was 17.24%. Compared to the two groups, there was only a significant difference in amantadine and placebo between the 4th week and the DRS score was significantly lower in the amantadine group than in the placebo group, and GOS score was significantly higher in the amantadine group than in the placebo group. However, in the sixth week and the end of the operation, the DRS and GOS values were not significant between the two groups.